Medlab has received an Intention to Grant notice from the European Patent Office for its patent covering the use of the company’s NanoCelle sub-micron delivery platform in Europe, including the UK.
The patent will be the second granted for NanoCelle following receipt of an Australian patent in September 2020. Medlab has also filed patent applications in the US, New Zealand, Singapore, Hong Kong and Canada.
Medlab CEO Dr Sean Hall said: “Receiving Notice of Intent from the European Patent Office represents another important validation of our NanoCelle drug-delivery platform, offering NanoCelle protection in one of the world’s largest markets.
“The grant will not only bolster the competitive advantage of our pharmaceutical and nutraceutical portfolio, it will also support our robust R&D pipeline and commercial partnering focus.”
NanoCelle creates nano-sized, water-soluble particles that enable optimised delivery of particles, overcoming issues with solubility and degradation.
It has potential applications in and out of medicine, including small and large molecule pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles.